Adverse effects of proton pump inhibitor drugs: Clues and conclusions

Current Opinion in Gastroenterology

Volumn 26, Issue 6, 2010, Pages 624-631

  McCarthy, Denis M ^a  

^a UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

Author keywords

carcinoid; fractures; hypergastrinemia; infections; malabsorption

Indexed keywords

CLOPIDOGREL; CYANOCOBALAMIN; DIDANOSINE; GASTRIN; INDINAVIR; IRON; KETOCONAZOLE; METHADONE; MIDAZOLAM; PROTON PUMP INHIBITOR; STEROID;

ALCOHOL CONSUMPTION; BACTERIAL OVERGROWTH; BACTERIAL PERITONITIS; CARCINOID; CLOSTRIDIUM DIFFICILE INFECTION; COMMUNITY ACQUIRED PNEUMONIA; CYANOCOBALAMIN DEFICIENCY; DIARRHEA; DRUG ABSORPTION; DRUG EXPOSURE; DRUG METABOLISM; DRUG SAFETY; EOSINOPHILIC ESOPHAGITIS; FOOD ALLERGY; FOREARM FRACTURE; GASTRITIS; GASTROESOPHAGEAL REFLUX; HIP FRACTURE; HUMAN; HYPERGASTRINEMIA; INFECTION RISK; INFECTION SENSITIVITY; INTESTINE INFECTION; IRON ABSORPTION; IRON DEFICIENCY ANEMIA; LONG TERM CARE; NONHUMAN; NUTRITIONAL STATUS; PATHOGENESIS; REVIEW; RISK FACTOR; SIDE EFFECT; SMALL INTESTINE; SMOKING; STOMACH EMPTYING; STOMACH PH; STOMACH SECRETION; WRIST FRACTURE;

CARCINOID TUMOR; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; COLITIS; DRUG INTERACTIONS; FRACTURES, BONE; GASTRIC ACID; HUMANS; INTESTINES; MALABSORPTION SYNDROMES; PERITONITIS; PROTON PUMP INHIBITORS; RISK FACTORS; STOMACH NEOPLASMS;

EID: 77958480781     PISSN: 02671379     EISSN: None     Source Type: Journal    
DOI: 10.1097/MOG.0b013e32833ea9d9     Document Type: Review

References (40)

1. Raghunath AS, O'Morain C, McLaughlin RC. The long-term use of proton pump inhibitors. Aliment Pharmacol Ther 2005; 22 (Suppl 1):55-63.
2. Ali T, Roberts DN, Tierney WM. Long-term safety concerns with proton pump inhibitors. Am J Med 2009; 122:896-903.
3. Lodato F, Azzaroli F, Turco L, Mazella N, et al. Adverse effects of proton pump inhibitors. Best Prac Res Clin Gastroenterol 2010; 24:193-201.
4. Thompson ABR, Sauve MD, Kassam N, Kamitakahara H. Safety of the long-term use of proton pump inhibitors. World J Gastroenterol 2010; 16:2323-2330.
5. Yang YX, Lewis JD, Epstein S, Metz DC, et al. Long-term proton pump inhibitor therapy and the risk of hip fracture. JAMA 2006; 296:2947-2953.
6. Vestergaard P, Rejnmark L, Mosekilde L. Proton pump inhibitors, histamine H2 receptor antagonists, and other antacid medications and the risk of fracture. Calcif Tissue Int 2006; 79:76-83.
7. TargownikLE, Lix LM, Metge CJ, Prior HJ, et al. Use of proton pump inhibitors and risk of osteoporotic fractures. CMAJ 2008; 179:319-326.
8. Gray SL, LaCroix AZ, Larso J, Robbins J, et al. Proton pump inhibitor use, hip fracture, and change in bone mineral density in postmenopausal women. Arch Int Med 2010; 170:765-771.
9. Targownik LE, Lix LM, Leung S, Leslie WD. Proton pump inhibitor use is not associated with osteoporosis or accelerated bone mineral density loss. Gastroenterology 2010; 138:896-904.
10. Merriman NA, Putt ME, Metz DC, Yang YX. Hip fracture risk in patients with a diagnosis of Pernicious Anemia. Gastroenterology 2010; 138:1330-1337.
11. Kaye JA, JickH. Proton pump inhibitor use and risk of hip fractures in patients without major risk factors. Pharmacotherapy 2008; 28:951-959.
12. Corley DA, Kubo A, Zhao W, Quesenberry C. Proton pump inhibitors and Histamine-2 receptor antagonists are associated with hip fractures among at-risk patients. Gastroenterology 2010; 139:93-101.
13. Larner AJ, Hamilton MIR. Review article: infective complications of therapeutic gastric acid inhibition. Aliment Pharmacol Ther 1994; 8:579-584.
14. Dial MS. Proton pump inhibitor use and enteric infections. Am J Gastroenterol 2009; 104 (S2):S10-S16.
15. Sonnenberg A. Temporal trends and geographical variations of peptic ulcer disease. Aliment Pharmacol Ther 1995; 9 (Suppl 2):3-12.
16. Leonard J, Marshall JK, Moayyedi P. Systematic review of the risk of enteric infection in patients taking acid suppression. Am J Gastroenterol 2007; 102:2047-2056.
17. Howell MD, Novack V, Grgurich P, Souillard D, et al. Iatrogenic gastric acid suppression and the risk of nosocomial Clostridium difficile infection. Arch Int Med 2010; 170:784-790.
18. Linsky A, Gupta K, Lawler E, Fonda J, et al. Proton pump inhibitors and risk for recurrent Clostridium difficile infection. Arch Int Med 2010; 170:772-778.
19. Sultan N, Nazareno J, Gregor J. Association between proton pump inhibitors and respiratory infections: a systematic review and meta-analysis of clinical trials. Can J Gastroenterol 2008; 22:761-766.
20. Murray LJ,GabelloM, Rudolph DS, Farrell CP, et al. Transmucosal gastric leak induced by proton pump inhibitors. Dig Dis Sci 2009; 54:1408-1417.
21. Lombardo L, Foti M, Ruggia O, Chiecchio A. Increased incidence of small intestinal bacterial overgrowth during proton pump inhibitor therapy. Clin Gastoenterol Hepatol 2010; 8:504-508.
22. Bajaj JS, Zadvornova Y, Heuman DM, Hafeezullah M, et al. Association of proton pump inhibitor therapy with spontaneous bacterial peritonitis in cirrhotic patients with ascites. Am J Gastroenterol 2009; 104:1130-1134.
23. McColl KEL Effect of proton pump inhibitors on vitamins and iron. Am J Gastroenterol 2009; 104:S3-S9.
24. Waldum HL, Qvigstad G, Fossmark R, et al. Rebound hypersecretion of acid from a physiological, pathophysiological and clinical point of view. Scand J Gastroenterol 2010; 45:389-394.
25. Reimer C, Sondergard B, Hilsted L, Bytzer P. Proton-pump inhibitor therapy induces acid related symptoms in healthy volunteers after withdrawal of therapy. Gastroenterology 2009; 137:80-87.
26. Sanaka M, Yamamoto T, Kuyama Y. Effects of proton pump inhibitors on gastric emptying: a systematic review. Dig Dis Sci 2010; 55:2431-2440.
27. Kuipers EJ. Proton pump inhibitors and gastric neoplasia. Gut 2006; 55:1217-1221.
28. Kuipers EJ. Barrett's esophagus, proton pump inhibitors and gastrin: the fog is clearing. Gut 2010; 59:148-149.
29. Wang JS, Varro A, Lightdale CJ, Lerkowit N, et al. Elevated serum gastrin is associated with a history of advanced neoplasia in Barrett's esophagus. Am J Gastroenterol 2010; 105:1039-1045.
30. Modlin IM, Lye KD, Kidd M. A 5-decade analysis of 13,715 carcinoid tumors. Cancer 2003; 97:934-959.
31. Modlin IM, Lye KD, Kidd M. A 50-year analysis of 562 gastric carcinoids: small tumor or larger problem? Am J Gastroenterol 2004; 99:23-32.
32. Hodgson N, Koniaris LG, Livingstone AS, Franceschi D. Gastric carcinoids: a temporal increase with proton pump inhibitor introduction. Surg Endosc 2005; 19:1610-1612.
33. Waldum H, Gustafsson B, Fossmark R, Qvigstad G. Antiulcer drugs and gastric cancer. Dig Dis Sci 2005; 50:S39-S44.
34. Merwat SN, Spechler SJ. Might the use of acid-suppressive medications predispose to the development of eosinophilic esophagitis? Am J Gastroenterol 2009; 104:1897-1902.
35. Sachmechu I, Reich DM, Wibowo AM, et al. Effect of proton pump inhibitors on serum thyroid-stimulating hormone level in euthyroid patients treated with levothyroxine for hypothyroidism. Endocr Pract 2007; 13:345-349.
36. Mega JL, Close SL, Wiviott SD, Shen L, et al. Cytochrome P-450 poly-morphisms and response to clopidogrel. N Engl J Med 2009; 360:354-362.
37. Chaudry AS, Kocchar R, Kohli KK. Genetic polymorphism of CYP2C1 9 and therapeutic response to proton pump inhibitors. Ind J Med Res 2008; 127:521-530.
38. Klotz U. Impact of CYP2C19 polymorphisms on the clinical action of proton pump inhibitors (PPIs). Euro J Clin Pharmacol 2009; 65:1-2.
39. Alkhatib AA, Elkhatib FA, Khatib OF. Gastric acid-reducing medications and clopidogrel: what are the latest FDA recommendations? Am J Gastroenterol 2010; 105:1211.
40. Ray WA, Murray KT, Griffin MR, Chung CP, et al. Outcomes with concurrent use of clopidogrel and proton pump inhibitors. Ann Int Med 2010; 152:337-345.